Biomarkers for drug development in early psychosis: Current issues and promising directions

European Neuropsychopharmacology

Volumn 26, Issue 6, 2016, Pages 923-937

  Goff, Donald C ^a   Romero, Klaus ^b   Paul, Jeffrey ^c   Mercedes Perez Rodriguez, M ^d   Crandall, David ^e   Potkin, Steven G ^f  

^a NEW YORK UNIVERSITY   (United States)

^b CRITICAL PATH INSTITUTE   (United States)

^c ASTELLAS PHARMA GLOBAL DEVELOPMENT   (United States)

^d MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^e DAINIPPON SUMITOMO PHARMA CO LTD   (Japan)

^f UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Biomarkers; Drug therapy; Genetics; Inflammation; Psychosis; Schizophrenia

Indexed keywords

BIOGENIC AMINE; BIOLOGICAL MARKER; ENDOCANNABINOID; GLUCOCORTICOID; GLUTAMIC ACID; HYDROCORTISONE; NEUROLEPTIC AGENT;

CEREBROSPINAL FLUID; GENETIC MARKER; HUMAN; INFLAMMATION; METHYLATION; NEUROIMAGING; OXIDATIVE STRESS; PRIORITY JOURNAL; PSYCHOSIS; REVIEW; STATISTICAL MODEL; TREATMENT RESPONSE; DIAGNOSTIC IMAGING; GENETICS; METABOLISM; SCHIZOPHRENIA;

ANTIPSYCHOTIC AGENTS; BIOMARKERS; HUMANS; PSYCHOTIC DISORDERS; SCHIZOPHRENIA;

EID: 84962491050     PISSN: 0924977X     EISSN: 18737862     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2016.01.009     Document Type: Review

References (142)

1. Aberg K.A., McClay J.L., Nerella S., Clark S., Kumar G., Chen W., Khachane A.N., Xie L., Hudson A., Gao G., Harada A., Hultman C.M., Sullivan P.F., Magnusson P.K., van den Oord E.J. Methylome-wide association study of schizophrenia: identifying blood biomarker signatures of environmental insults. JAMA Psychiatry 2014, 71:255-264.
2. Alekseyenko A.V., Lytkin N.I., Ai J., Ding B., Padyukov L., Aliferis C.F., Statnikov A. Causal graph-based analysis of genome-wide association data in rheumatoid arthritis. Biol. Direct 2011, 6:25.
3. Aleksovska K., Leoncini E., Bonassi S., Cesario A., Boccia S., Frustaci A. Systematic review and meta-analysis of circulating S100B blood levels in schizophrenia. PloS One 2014, 9:e106342.
4. Alfredsson G., Wiesel F.A., Tylec A. Relationships between glutamate and monoamine metabolites in cerebrospinal fluid and serum in healthy volunteers. Biol. Psychiatry 1988, 23:689-697.
5. Aluise C.D., Sowell R.A., Butterfield D.A. Peptides and proteins in plasma and cerebrospinal fluid as biomarkers for the prediction, diagnosis, and monitoring of therapeutic efficacy of Alzheimer's disease. Biochim. Biophys. Acta 2008, 1782:549-558.
6. Andreassen O.A., Thompson W.K., Dale A.M. Boosting the power of schizophrenia genetics by leveraging new statistical tools. Schizophr. Bull. 2014, 40:13-17.
7. Apud J.A., Mattay V., Chen J., Kolachana B.S., Callicott J.H., Rasetti R., Alce G., Iudicello J.E., Akbar N., Egan M.F., Goldberg T.E., Weinberger D.R. Tolcapone improves cognition and cortical information processing in normal human subjects. Neuropsychopharmacology 2007, 32:1011-1020.
8. Athanasiou M.C., Dettling M., Cascorbi I., Mosyagin I., Salisbury B.A., Pierz K.A., Zou W., Whalen H., Malhotra A.K., Lencz T., Gerson S.L., Kane J.M., Reed C.R. Candidate gene analysis identifies a polymorphism in HLA-DQB1 associated with clozapine-induced agranulocytosis. J. Clin. Psychiatry 2011, 72:458-463.
9. Auta J., Smith R.C., Dong E., Tueting P., Sershen H., Boules S., Lajtha A., Davis J., Guidotti A. DNA-methylation gene network dysregulation in peripheral blood lymphocytes of schizophrenia patients. Schizophr. Res. 2013, 150:312-318.
10. BDWG B.D.W.G. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin. Pharmacol. Ther. 2001, 69:89-95.
11. Beckmann H., Gattaz W.F. Multidimensional analysis of the concentrations of 17 substances in the CSF of schizophrenics and controls. J. Neural Transm. 2002, 109:931-938.
12. Behrens M.M., Sejnowski T.J. Does schizophrenia arise from oxidative dysregulation of parvalbumin-interneurons in the developing cortex?. Neuropharmacology 2009, 57:193-200.
13. Ben-Shachar D., Livne E., Spanier I., Leenders K.L., Youdim M.B. Typical and atypical neuroleptics induce alteration in blood-brain barrier and brain 59FeCl3 uptake. J. Neurochem. 1994, 62:1112-1118.
14. Bioque M., Garcia-Bueno B., Macdowell K.S., Meseguer A., Saiz P.A., Parellada M., Gonzalez-Pinto A., Rodriguez-Jimenez R., Lobo A., Leza J.C., Bernardo M. Peripheral endocannabinoid system dysregulation in first-episode psychosis. Neuropsychopharmacology 2013, 38:2568-2577.
15. Bowling H., Zhang G., Bhattacharya A., Perez-Cuesta L.M., Deinhardt K., Hoeffer C.A., Neubert T.A., Gan W.B., Klann E., Chao M.V. Antipsychotics activate mTORC1-dependent translation to enhance neuronal morphological complexity. Sci. Signal 2014, 7. ra4.
16. Brennand K.J., Simone A., Jou J., Gelboin-Burkhart C., Tran N., Sangar S., Li Y., Mu Y., Chen G., Yu D., McCarthy S., Sebat J., Gage F.H. Modelling schizophrenia using human induced pluripotent stem cells. Nature 2011, 473:221-225.
17. Brett F.M., Mizisin A.P., Powell H.C., Campbell I.L. Evolution of neuropathologic abnormalities associated with blood-brain barrier breakdown in transgenic mice expressing interleukin-6 in astrocytes. J. Neuropathol. Exp. Neurol. 1995, 54:766-775.
18. Bsibsi M., Peferoen L.A., Holtman I.R., Nacken P.J., Gerritsen W.H., Witte M.E., van Horssen J., Eggen B.J., van der Valk P., Amor S., van Noort J.M. Demyelination during multiple sclerosis is associated with combined activation of microglia/macrophages by IFN-gamma and alpha B-crystallin. Acta Neuropathol. 2014, 128:215-229.
19. Cannon T.D., Chung Y., He G., Sun D., Jacobson A., van Erp T.G., McEwen S., Addington J., Bearden C.E., Cadenhead K., Cornblatt B., Mathalon D.H., McGlashan T., Perkins D., Jeffries C., Seidman L.J., Tsuang M., Walker E., Woods S.W., Heinssen R. Progressive reduction in cortical thickness as psychosis develops: a multisite longitudinal neuroimaging study of youth at elevated clinical risk. Biol. Psychiatry 2014.
20. Carter C.J. Schizophrenia susceptibility genes directly implicated in the life cycles of pathogens: cytomegalovirus, influenza, herpes simplex, rubella, and Toxoplasma gondii. Schizophr. Bull. 2009, 35:1163-1182.
21. Cattaneo A., Gennarelli M., Uher R., Breen G., Farmer A., Aitchison K.J., Craig I.W., Anacker C., Zunsztain P.A., McGuffin P., Pariante C.M. Candidate genes expression profile associated with antidepressants response in the GENDEP study: differentiating between baseline'predictors' and longitudinal'targets'. Neuropsychopharmacology 2013, 38:377-385.
22. Ceccarini J., De Hert M., Van Winkel R., Peuskens J., Bormans G., Kranaster L., Enning F., Koethe D., Leweke F.M., Van Laere K. Increased ventral striatal CB1 receptor binding is related to negative symptoms in drug-free patients with schizophrenia. NeuroImage 2013, 79:304-312.
23. Chen Z., Jalabi W., Hu W., Park H.J., Gale J.T., Kidd G.J., Bernatowicz R., Gossman Z.C., Chen J.T., Dutta R., Trapp B.D. Microglial displacement of inhibitory synapses provides neuroprotection in the adult brain. Nat. Commun. 2014, 5:4486.
24. Condray R., Dougherty G.G., Jr, Keshavan M.S., Reddy R.D., Haas G.L., Montrose D.M., Matson W.R., McEvoy J., Kaddurah-Daouk R., Yao J.K. 3-Hydroxykynurenine and clinical symptoms in first-episode neuroleptic-naive patients with schizophrenia. Int. J. Neuropsychopharmacol. 2011, 14:756-767.
25. Delalle I., Kao P.F., Choi J. Deregulated microRNA in biospecimens from patients diagnosed with schizophrenia and bipolar disorder as a disease marker. Transl. Neurosci. 2014, 5:173-178.
26. Díaz-Caneja C.M., Pina-Camacho L., Rodríguez-Quiroga A., Fraguas D., Parellada M., Arango C. Predictors of outcome in early-onset psychosis: a systematic review. Schizophrenia 2015.
27. Doorduin J., de Vries E.F., Dierckx R.A., Klein H.C. PET imaging of the peripheral benzodiazepine receptor: monitoring disease progression and therapy response in neurodegenerative disorders. Curr. Pharm. Des. 2008, 14:3297-3315.
28. Drexhage R.C., Hoogenboezem T.A., Cohen D., Versnel M.A., Nolen W.A., van Beveren N.J., Drexhage H.A. An activated set point of T-cell and monocyte inflammatory networks in recent-onset schizophrenia patients involves both pro- and anti-inflammatory forces. Int. J. Neuropsychopharmacol. 2011, 14:746-755.
29. Drozda K., Muller D.J., Bishop J.R. Pharmacogenomic testing for neuropsychiatric drugs: current status of drug labeling, guidelines for using genetic information, and test options. Pharmacotherapy 2014, 34:166-184.
30. Eack S.M., Greenwald D.P., Hogarty S.S., Cooley S.J., DiBarry A.L., Montrose D.M., Keshavan M.S. Cognitive enhancement therapy for early-course schizophrenia: effects of a two-year randomized controlled trial. Psychiatr. Serv. 2009, 60:1468-1476.
31. English J.A., Pennington K., Dunn M.J., Cotter D.R. The neuroproteomics of schizophrenia. Biol. Psychiatry 2011, 69:163-172.
32. Evins A., Amico E., Shih V., Goff D. Clozapine treatment increases serum glutamate and aspartate compared to conventional neuroleptics. J. Neural Transm. 1997, 104:761-766.
33. Fawzi M.H., Fawzi M.M., Fawzi M.M., Said N.S. C-reactive protein serum level in drug-free male Egyptian patients with schizophrenia. Psychiatry Res. 2011, 190:91-97.
34. FDA Guidance for Industry and FDA Staff- Qualification Process for Drug Development Tools. U.S. Department of Health and Human Services, F.a.D.A., Center for Drug Evaluation and Research (CDER) 2014, Silver Spring, MD. Ed.
35. Fienberg A.A., Hiroi N., Mermelstein P.G., Song W., Snyder G.L., Nishi A., Cheramy A., O'Callaghan J.P., Miller D.B., Cole D.G., Corbett R., Haile C.N., Cooper D.C., Onn S.P., Grace A.A., Ouimet C.C., White F.J., Hyman S.E., Surmeier D.J., Girault J., Nestler E.J., Greengard P. DARPP-32: regulator of the efficacy of dopaminergic neurotransmission. Science (New York, N. Y. 1998, 281:838-842.
36. Fraguas D., Gonzalez-Pinto A., Mico J.A., Reig S., Parellada M., Martinez-Cengotitabengoa M., Castro-Fornieles J., Rapado-Castro M., Baeza I., Janssen J., Desco M., Leza J.C., Arango C. Decreased glutathione levels predict loss of brain volume in children and adolescents with first-episode psychosis in a two-year longitudinal study. Schizophr. Res. 2012, 137:58-65.
37. Franke T.F. PI3K/Akt: getting it right matters. Oncogene 2008, 27:6473-6488.
38. Freudenreich O., Brockman M.A., Henderson D.C., Evins A.E., Fan X., Walsh J.P., Goff D.C. Analysis of peripheral immune activation in schizophrenia using quantitative reverse-transcription polymerase chain reaction (RT-PCR). Psychiatry Res. 2010, 176:99-102.
39. Garay P.A., Hsiao E.Y., Patterson P.H., McAllister A.K. Maternal immune activation causes age- and region-specific changes in brain cytokines in offspring throughout development. Brain Behav. Immun. 2013, 31:54-68.
40. Gilmore J.H., Jarskog L.F. Exposure to infection and brain development: cytokines in the pathogenesis of schizophrenia. Schizophr. Res. 1997, 24:365-367.
41. Glatt S.J., Everall I.P., Kremen W.S., Corbeil J., Sasik R., Khanlou N., Han M., Liew C.C., Tsuang M.T. Comparative gene expression analysis of blood and brain provides concurrent validation of SELENBP1 up-regulation in schizophrenia. Proc. Natl. Acad. Sci. USA 2005, 102:15533-15538.
42. Goff D.C., Hennen J., Tsai G., Evins A.E., Yurgelun-Todd D., Renshaw P. Modulation of brain and serum glutamatergic concentrations following a switch from conventional neuroleptics to olanzapine. Biol. Psychiatry 2002, 51:493-497.
43. Groeneweg F.L., Karst H., de Kloet E.R., Joels M. Rapid non-genomic effects of corticosteroids and their role in the central stress response. J. Endocrinol. 2011, 209:153-167.
44. Hannestad J., Gallezot J.D., Schafbauer T., Lim K., Kloczynski T., Morris E.D., Carson R.E., Ding Y.S., Cosgrove K.P. Endotoxin-induced systemic inflammation activates microglia: [(11)C]PBR28 positron emission tomography in nonhuman primates. NeuroImage 2012, 63:232-239.
45. Haroutunian V., Katsel P., Dracheva S., Stewart D.G., Davis K.L. Variations in oligodendrocyte-related gene expression across multiple cortical regions: implications for the pathophysiology of schizophrenia. Int. J. Neuropsychopharmacol. 2007, 10:565-573.
46. Hosnijeh F.S., Krop E.J., Portengen L., Rabkin C.S., Linseisen J., Vineis P., Vermeulen R. Stability and reproducibility of simultaneously detected plasma and serum cytokine levels in asymptomatic subjects. Biomarkers 2010, 15:140-148.
47. Huang J.T., Leweke F.M., Oxley D., Wang L., Harris N., Koethe D., Gerth C.W., Nolden B.M., Gross S., Schreiber D., Reed B., Bahn S. Disease biomarkers in cerebrospinal fluid of patients with first-onset psychosis. PLoS Med. 2006, 3:e428.
48. Ito H.T., Smith S.E., Hsiao E., Patterson P.H. Maternal immune activation alters nonspatial information processing in the hippocampus of the adult offspring. Brain Behav. Immun. 2010, 24:930-941.
49. Javitt D.C. Distress intolerance, kynurenic acid, and schizophrenia. JAMA Psychiatry 2014, 71:749-750.
50. Johanson C.E., Duncan J.A.3rd, Klinge P.M., Brinker T., Stopa E.G., Silverberg G.D. Multiplicity of cerebrospinal fluid functions: New challenges in health and disease. Cerebrospinal Fluid Res. 2008, 5:10.
51. Kao A.C., Muller D.J. Genetics of antipsychotic-induced weight gain: update and current perspectives. Pharmacogenomics 2013, 14:2067-2083.
52. Karanikas E., Antoniadis D., Garyfallos G.D. The role of cortisol in first episode of psychosis: a systematic review. Curr. Psychiatry Rep. 2014, 16:503.
53. Kenk M., Selvanathan T., Rao N., Suridjan I., Rusjan P., Remington G., Meyer J.H., Wilson A.A., Houle S., Mizrahi R. Imaging neuroinflammation in gray and white matter in schizophrenia: an in-vivo PET study with [18F]-FEPPA. Schizophr. Bull. 2014.
54. Kirov I.I., George I.C., Jayawickrama N., Babb J.S., Perry N.N., Gonen O. Longitudinal inter- and intra-individual human brain metabolic quantification over 3 years with proton MR spectroscopy at 3 T. Magn. Reson. Med. 2012, 67:27-33.
55. Klein A.B., Williamson R., Santini M.A., Clemmensen C., Ettrup A., Rios M., Knudsen G.M., Aznar S. Blood BDNF concentrations reflect brain-tissue BDNF levels across species. Int. J. Neuropsychopharmacol. 2011, 14:347-353.
56. Knuesel I., Chicha L., Britschgi M., Schobel S.A., Bodmer M., Hellings J.A., Toovey S., Prinssen E.P. Maternal immune activation and abnormal brain development across CNS disorders. Nat. Rev. Neurol. 2014, 10:643-660.
57. Koethe D., Giuffrida A., Schreiber D., Hellmich M., Schultze-Lutter F., Ruhrmann S., Klosterkotter J., Piomelli D., Leweke F.M. Anandamide elevation in cerebrospinal fluid in initial prodromal states of psychosis. Br. J. Psychiatry 2009, 194:371-372.
58. Kraguljac N.V., White D.M., Reid M.A., Lahti A.C. Increased hippocampal glutamate and volumetric deficits in unmedicated patients with schizophrenia. JAMA Psychiatry 2013, 70:1294-1302.
59. Kumarasinghe N., Beveridge N.J., Gardiner E., Scott R.J., Yasawardene S., Perera A., Mendis J., Suriyakumara K., Schall U., Tooney P.A. Gene expression profiling in treatment-naive schizophrenia patients identifies abnormalities in biological pathways involving AKT1 that are corrected by antipsychotic medication. Int. J. Neuropsychopharmacol. 2013, 16:1483-1503.
60. LaSalle J.M. A genomic point-of-view on environmental factors influencing the human brain methylome. Epigenetics 2011, 6:862-869.
61. Lavebratt C., Olsson S., Backlund L., Frisen L., Sellgren C., Priebe L., Nikamo P., Traskman-Bendz L., Cichon S., Vawter M.P., Osby U., Engberg G., Landen M., Erhardt S., Schalling M. The KMO allele encoding Arg452 is associated with psychotic features in bipolar disorder type 1, and with increased CSF KYNA level and reduced KMO expression. Mol. Psychiatry 2014, 19:334-341.
62. Leweke F.M., Giuffrida A., Koethe D., Schreiber D., Nolden B.M., Kranaster L., Neatby M.A., Schneider M., Gerth C.W., Hellmich M., Klosterkotter J., Piomelli D. Anandamide levels in cerebrospinal fluid of first-episode schizophrenic patients: impact of cannabis use. Schizophr. Res. 2007, 94:29-36.
63. Leweke F.M., Piomelli D., Pahlisch F., Muhl D., Gerth C.W., Hoyer C., Klosterkotter J., Hellmich M., Koethe D. Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Transl. Psychiatry 2012, 2:e94.
64. Li M.D., Kane J.K., Matta S.G., Blaner W.S., Sharp B.M. Nicotine enhances the biosynthesis and secretion of transthyretin from the choroid plexus in rats: implications for beta-amyloid formation. J. Neurosci. 2000, 20:1318-1323.
65. Linderholm K.R., Skogh E., Olsson S.K., Dahl M.L., Holtze M., Engberg G., Samuelsson M., Erhardt S. Increased levels of kynurenine and kynurenic acid in the CSF of patients with schizophrenia. Schizophr. Bull. 2012, 38:426-432.
66. Lisman J.E., Coyle J.T., Green R.W., Javitt D.C., Benes F.M., Heckers S., Grace A.A. Circuit-based framework for understanding neurotransmitter and risk gene interactions in schizophrenia. Trends Neurosci. 2008, 31:234-242.
67. Luque-Garcia J.L., Neubert T.A. Sample preparation for serum/plasma profiling and biomarker identification by mass spectrometry. J. Chromatogr. A 2007, 1153:259-276.
68. Malhotra A.K., Correll C.U., Chowdhury N.I., Muller D.J., Gregersen P.K., Lee A.T., Tiwari A.K., Kane J.M., Fleischhacker W.W., Kahn R.S., Ophoff R.A., Meltzer H.Y., Lencz T., Kennedy J.L. Association between common variants near the melanocortin 4 receptor gene and severe antipsychotic drug-induced weight gain. Arch. Gen. Psychiatry 2012, 69:904-912.
69. Manoach D.S., Demanuele C., Wamsley E.J., Vangel M., Montrose D.M., Miewald J., Kupfer D., Buysse D., Stickgold R., Keshavan M.S. Sleep spindle deficits in antipsychotic-naive early course schizophrenia and in non-psychotic first-degree relatives. Front. Hum. Neurosci. 2014, 8:762.
70. Martin-Facklam M., Pizzagalli F., Zhou Y., Ostrowitzki S., Raymont V., Brasic J.R., Parkar N., Umbricht D., Dannals R.F., Goldwater R., Wong D.F. Glycine transporter type 1 occupancy by bitopertin: a positron emission tomography study in healthy volunteers. Neuropsychopharmacology 2013, 38:504-512.
71. Martin A.K., Robinson G., Reutens D., Mowry B. Copy number deletion burden is associated with cognitive, structural, and resting-state network differences in patients with schizophrenia. Behav. Brain Res. 2014, 272:324-334.
72. Martinez-Cengotitabengoa M., Mac-Dowell K.S., Leza J.C., Mico J.A., Fernandez M., Echevarria E., Sanjuan J., Elorza J., Gonzalez-Pinto A. Cognitive impairment is related to oxidative stress and chemokine levels in first psychotic episodes. Schizophr. Res. 2012, 137:66-72.
73. McEwen B.S. Neuroscience. Hormones and the social brain. Science (New York, N. Y. 2013, 339:279-280.
74. Meeker R.B., Poulton W., Markovic-Plese S., Hall C., Robertson K. Protein changes in CSF of HIV-infected patients: evidence for loss of neuroprotection. J. Neurovirol. 2011, 17:258-273.
75. Meyer U. Developmental neuroinflammation and schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 2013, 42:20-34.
76. Mihaylova M.M., Shaw R.J. The AMPK signalling pathway coordinates cell growth, autophagy and metabolism. Nat. Cell Biol. 2011, 13:1016-1023.
77. Millan M.J., Bales K.L. Towards improved animal models for evaluating social cognition and its disruption in schizophrenia: the CNTRICS initiative. Neurosci. Biobehav. Rev. 2013, 37:2166-2180.
78. Miller B.J., Buckley P., Seabolt W., Mellor A., Kirkpatrick B. Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biol. Psychiatry 2011, 70:663-671.
79. Mondelli V., Cattaneo A., Belvederi Murri M., Di Forti M., Handley R., Hepgul N., Miorelli A., Navari S., Papadopoulos A.S., Aitchison K.J., Morgan C., Murray R.M., Dazzan P., Pariante C.M. Stress and inflammation reduce brain-derived neurotrophic factor expression in first-episode psychosis: a pathway to smaller hippocampal volume. J. Clin. Psychiatry 2011, 72:1677-1684.
80. Mondelli V., Dazzan P., Hepgul N., Di Forti M., Aas M., D'Albenzio A., Di Nicola M., Fisher H., Handley R., Marques T.R., Morgan C., Navari S., Taylor H., Papadopoulos A., Aitchison K.J., Murray R.M., Pariante C.M. Abnormal cortisol levels during the day and cortisol awakening response in first-episode psychosis: the role of stress and of antipsychotic treatment. Schizophr. Res. 2010, 116:234-242.
81. Monin A., Baumann P.S., Griffa A., Xin L., Mekle R., Fournier M., Butticaz C., Klaey M., Cabungcal J.H., Steullet P., Ferrari C., Cuenod M., Gruetter R., Thiran J.P., Hagmann P., Conus P., Do K.Q. Glutathione deficit impairs myelin maturation: relevance for white matter integrity in schizophrenia patients. Mol. Psychiatry 2014.
82. Muller N., Ackenheil M. Immunoglobulin and albumin content of cerebrospinal fluid in schizophrenic patients: relationship to negative symptomatology. Schizophr. Res. 1995, 14:223-228.
83. Niwa M., Jaaro-Peled H., Tankou S., Seshadri S., Hikida T., Matsumoto Y., Cascella N.G., Kano S., Ozaki N., Nabeshima T., Sawa A. Adolescent stress-induced epigenetic control of dopaminergic neurons via glucocorticoids. Science (New York, N. Y.) 2013, 339:335-339.
84. O'Connor M.F., Irwin M.R., Wellisch D.K. When grief heats up: pro-inflammatory cytokines predict regional brain activation. NeuroImage 2009, 47:891-896.
85. Obeid R., Kostopoulos P., Knapp J.P., Kasoha M., Becker G., Fassbender K., Herrmann W. Biomarkers of folate and vitamin B12 are related in blood and cerebrospinal fluid. Clin. Chem. 2007, 53:326-333.
86. Olney J.W., Farber N.B. Glutamate receptor dysfunction and schizophrenia. Arch. Gen. Psychiatry 1995, 52:998-1007.
87. Olsson S.K., Samuelsson M., Saetre P., Lindstrom L., Jonsson E.G., Nordin C., Engberg G., Erhardt S., Landen M. Elevated levels of kynurenic acid in the cerebrospinal fluid of patients with bipolar disorder. J. Psychiatry Neurosci. 2010, 35:195-199.
88. Ortega-Alvaro A., Aracil-Fernandez A., Garcia-Gutierrez M.S., Navarrete F., Manzanares J. Deletion of CB2 cannabinoid receptor induces schizophrenia-related behaviors in mice. Neuropsychopharmacology 2011, 36:1489-1504.
89. Oskvig D.B., Elkahloun A.G., Johnson K.R., Phillips T.M., Herkenham M. Maternal immune activation by LPS selectively alters specific gene expression profiles of interneuron migration and oxidative stress in the fetus without triggering a fetal immune response. Brain Behav. Immun. 2012, 26:623-634.
90. Owen D.R., Yeo A.J., Gunn R.N., Song K., Wadsworth G., Lewis A., Rhodes C., Pulford D.J., Bennacef I., Parker C.A., StJean P.L., Cardon L.R., Mooser V.E., Matthews P.M., Rabiner E.A., Rubio J.P. An 18-kDa translocator protein (TSPO) polymorphism explains differences in binding affinity of the PET radioligand PBR28. J. Cereb. Blood Flow Metab. 2012, 32:1-5.
91. Pagliaccio D., Luby J.L., Bogdan R., Agrawal A., Gaffrey M.S., Belden A.C., Botteron K.N., Harms M.P., Barch D.M. Stress-system genes and life stress predict cortisol levels and amygdala and hippocampal volumes in children. Neuropsychopharmacology 2014, 39:1245-1253.
92. Pang Y., Rodts-Palenik S., Cai Z., Bennett W.A., Rhodes P.G. Suppression of glial activation is involved in the protection of IL-10 on maternal E. coli induced neonatal white matter injury. Brain Res. Dev. Brain Res. 2005, 157:141-149.
93. Perez-Rodriguez M.M., Mahon K., Russo M., Ungar A.K., Burdick K.E. Oxytocin and social cognition in affective and psychotic disorders. Eur. Neuropsychopharmacol. 2014.
94. Pietersen C.Y., Mauney S.A., Kim S.S., Lim M.P., Rooney R.J., Goldstein J.M., Petryshen T.L., Seidman L.J., Shenton M.E., McCarley R.W., Sonntag K.C., Woo T.U. Molecular profiles of pyramidal neurons in the superior temporal cortex in schizophrenia. J. Neurogenet. 2014, 28:53-69.
95. Pietersen C.Y., Mauney S.A., Kim S.S., Passeri E., Lim M.P., Rooney R.J., Goldstein J.M., Petreyshen T.L., Seidman L.J., Shenton M.E., McCarley R.W., Sonntag K.C., Woo T.U. Molecular profiles of parvalbumin-immunoreactive neurons in the superior temporal cortex in schizophrenia. J. Neurogenet. 2014, 28:70-85.
96. Pillai A., Kale A., Joshi S., Naphade N., Raju M.S., Nasrallah H., Mahadik S.P. Decreased BDNF levels in CSF of drug-naive first-episode psychotic subjects: correlation with plasma BDNF and psychopathology. Int. J. Neuropsychopharmacol. 2010, 13:535-539.
97. Pistis M., Ferraro L., Pira L., Flore G., Tanganelli S., Gessa G.L., Devoto P. Delta(9)-tetrahydrocannabinol decreases extracellular GABA and increases extracellular glutamate and dopamine levels in the rat prefrontal cortex: an in vivo microdialysis study. Brain Res. 2002, 948:155-158.
98. Plog B.A., Dashnaw M.L., Hitomi E., Peng W., Liao Y., Lou N., Deane R., Nedergaard M. Biomarkers of traumatic injury are transported from brain to blood via the glymphatic system. J. Neurosci. 2015, 35:518-526.
99. Poste G., Compton C.C., Barker A.D. The national biomarker development alliance: confronting the poor productivity of biomarker research and development. Expert Rev. Mol. Diagn. 2014, 1-8.
100. Potkin S.G., Keator D.B., Kesler-West M.L., Nguyen D.D., van Erp T.G., Mukherjee J., Shah N., Preda A. D2 receptor occupancy following lurasidone treatment in patients with schizophrenia or schizoaffective disorder. CNS Spectr. 2014, 19:176-181.
101. Potkin S.G., Macciardi F., Guffanti G., Fallon J.H., Wang Q., Turner J.A., Lakatos A., Miles M.F., Lander A., Vawter M.P., Xie X. Identifying gene regulatory networks in schizophrenia. NeuroImage 2010, 53:839-847.
102. Potkin S.G., Turner J.A., Guffanti G., Lakatos A., Fallon J.H., Nguyen D.D., Mathalon D., Ford J., Lauriello J., Macciardi F. A genome-wide association study of schizophrenia using brain activation as a quantitative phenotype. Schizophr. Bull. 2009, 35:96-108.
103. Prabakaran S., Swatton J.E., Ryan M.M., Huffaker S.J., Huang J.T., Griffin J.L., Wayland M., Freeman T., Dudbridge F., Lilley K.S., Karp N.A., Hester S., Tkachev D., Mimmack M.L., Yolken R.H., Webster M.J., Torrey E.F., Bahn S. Mitochondrial dysfunction in schizophrenia: evidence for compromised brain metabolism and oxidative stress. Mol. Psychiatry 2004, 9(684-697):643.
104. Pruessner J.C., Champagne F., Meaney M.J., Dagher A. Dopamine release in response to a psychological stress in humans and its relationship to early life maternal care: a positron emission tomography study using [11C]raclopride. J. Neurosci. 2004, 24:2825-2831.
105. Ray B., Henaff M., Ma S., Efstathiadis E., Peskin E.R., Picone M., Poli T., Aliferis C.F., Statnikov A. Information content and analysis methods for multi-modal high-throughput biomedical data. Sci. Rep. 2014, 4:4411.
106. Ripke S., O'Dushlaine C., Chambert K., Moran J.L., Kahler A.K., Akterin S., Bergen S.E., Collins A.L., Crowley J.J., Fromer M., Kim Y., Lee S.H., Magnusson P.K., Sanchez N., Stahl E.A., Williams S., Wray N.R., Xia K., Bettella F., Borglum A.D., Bulik-Sullivan B.K., Cormican P., Craddock N., de Leeuw C., Durmishi N., Gill M., Golimbet V., Hamshere M.L., Holmans P., Hougaard D.M., Kendler K.S., Lin K., Morris D.W., Mors O., Mortensen P.B., Neale B.M., O'Neill F.A., Owen M.J., Milovancevic M.P., Posthuma D., Powell J., Richards A.L., Riley B.P., Ruderfer D., Rujescu D., Sigurdsson E., Silagadze T., Smit A.B., Stefansson H., Steinberg S., Suvisaari J., Tosato S., Verhage M., Walters J.T., Levinson D.F., Gejman P.V., Laurent C., Mowry B.J., O'Donovan M.C., Pulver A.E., Schwab S.G., Wildenauer D.B., Dudbridge F., Shi J., Albus M., Alexander M., Campion D., Cohen D., Dikeos D., Duan J., Eichhammer P., Godard S., Hansen M., Lerer F.B., Liang K.Y., Maier W., Mallet J., Nertney D.A., Nestadt G., Norton N., Papadimitriou G.N., Ribble R., Sanders A.R., Silverman J.M., Walsh D., Williams N.M., Wormley B., Arranz M.J., Bakker S., Bender S., Bramon E., Collier D., Crespo-Facorro B., Hall J., Iyegbe C., Jablensky A., Kahn R.S., Kalaydjieva L., Lawrie S., Lewis C.M., Linszen D.H., Mata I., McIntosh A., Murray R.M., Ophoff R.A., Van Os J., Walshe M., Weisbrod M., Wiersma D., Donnelly P., Barroso I., Blackwell J.M., Brown M.A., Casas J.P., Corvin A.P., Deloukas P., Duncanson A., Jankowski J., Markus H.S., Mathew C.G., Palmer C.N., Plomin R., Rautanen A., Sawcer S.J., Trembath R.C., Viswanathan A.C., Wood N.W., Spencer C.C., Band G., Bellenguez C., Freeman C., Hellenthal G., Giannoulatou E., Pirinen M., Pearson R.D., Strange A., Su Z., Vukcevic D., Langford C., Hunt S.E., Edkins S., Gwilliam R., Blackburn H., Bumpstead S.J., Dronov S., Gillman M., Gray E., Hammond N., Jayakumar A., McCann O.T., Liddle J., Potter S.C., Ravindrarajah R., Ricketts M., Tashakkori-Ghanbaria A., Waller M.J., Weston P., Widaa S., Whittaker P., McCarthy M.I., Stefansson K., Scolnick E., Purcell S., McCarroll S.A., Sklar P., Hultman C.M., Sullivan P.F. Genome-wide association analysis identifies 13 new risk loci for schizophrenia. Nat. Genet. 2013, 45:1150-1159.
107. Ripke S., Sanders A.R., Kendler K.S., Levinson D.F., Sklar P., Holmans P.A., Lin D.Y., Duan J., Ophoff R.A., Andreassen O.A., Scolnick E., Cichon S., St, Clair D., Corvin A., Gurling H., Werge T., Rujescu D., Blackwood D.H., Pato C.N., Malhotra A.K., Purcell S., Dudbridge F., Neale B.M., Rossin L., Visscher P.M., Posthuma D., Ruderfer D.M., Fanous A., Stefansson H., Steinberg S., Mowry B.J., Golimbet V., De Hert M., Jonsson E.G., Bitter I., Pietilainen O.P., Collier D.A., Tosato S., Agartz I., Albus M., Alexander M., Amdur R.L., Amin F., Bass N., Bergen S.E., Black D.W., Borglum A.D., Brown M.A., Bruggeman R., Buccola N.G., Byerley W.F., Cahn W., Cantor R.M., Carr V.J., Catts S.V., Choudhury K., Cloninger C.R., Cormican P., Craddock N., Danoy P.A., Datta S., de Haan L., Demontis D., Dikeos D., Djurovic S., Donnelly P., Donohoe G., Duong L., Dwyer S., Fink-Jensen A., Freedman R., Freimer N.B., Friedl M., Georgieva L., Giegling I., Gill M., Glenthoj B., Godard S., Hamshere M., Hansen M., Hansen T., Hartmann A.M., Henskens F.A., Hougaard D.M., Hultman C.M., Ingason A., Jablensky A.V., Jakobsen K.D., Jay M., Jurgens G., Kahn R.S., Keller M.C., Kenis G., Kenny E., Kim Y., Kirov G.K., Konnerth H., Konte B., Krabbendam L., Krasucki R., Lasseter V.K., Laurent C., Lawrence J., Lencz T., Lerer F.B., Liang K.Y., Lichtenstein P., Lieberman J.A., Linszen D.H., Lonnqvist J., Loughland C.M., Maclean A.W., Maher B.S., Maier W., Mallet J., Malloy P., Mattheisen M., Mattingsdal M., McGhee K.A., McGrath J.J., McIntosh A., McLean D.E., McQuillin A., Melle I., Michie P.T., Milanova V., Morris D.W., Mors O., Mortensen P.B., Moskvina V., Muglia P., Myin-Germeys I., Nertney D.A., Nestadt G., Nielsen J., Nikolov I., Nordentoft M., Norton N., Nothen M.M., O'Dushlaine C.T., Olincy A., Olsen L., O'Neill F.A., Orntoft T.F., Owen M.J., Pantelis C., Papadimitriou G., Pato M.T., Peltonen L., Petursson H., Pickard B., Pimm J., Pulver A.E., Puri V., Quested D., Quinn E.M., Rasmussen H.B., Rethelyi J.M., Ribble R., Rietschel M., Riley B.P., Ruggeri M., Schall U., Schulze T.G., Schwab S.G., Scott R.J., Shi J., Sigurdsson E., Silverman J.M., Spencer C.C., Stefansson K., Strange A., Strengman E., Stroup T.S., Suvisaari J., Terenius L., Thirumalai S., Thygesen J.H., Timm S., Toncheva D., van den Oord E., van Os J., van Winkel R., Veldink J., Walsh D., Wang A.G., Wiersma D., Wildenauer D.B., Williams H.J., Williams N.M., Wormley B., Zammit S., Sullivan P.F., O'Donovan M.C., Daly M.J., Gejman P.V. Genome-wide association study identifies five new schizophrenia loci. Nat. Genet. 2011, 43:969-976.
108. Roffman J.L., Brohawn D.G., Nitenson A.Z., Macklin E.A., Smoller J.W., Goff D.C. Genetic variation throughout the folate metabolic pathway influences negative symptom severity in schizophrenia. Schizophr. Bull. 2011.
109. Roffman J.L., Lamberti J.S., Achtyes E., Macklin E.A., Galendez G.C., Raeke L.H., Silverstein N.J., Smoller J.W., Hill M., Goff D.C. Randomized Multicenter Investigation of Folate Plus Vitamin B12 Supplementation in Schizophrenia. JAMA Psychiatry 2013, 1-9.
110. Rosell D.R., Zaluda L.C., McClure M.M., Perez-Rodriguez M.M., Strike K.S., Barch D.M., Harvey P.D., Girgis R.R., Hazlett E.A., Mailman R.B., Abi-Dargham A., Lieberman J.A., Siever L.J. Effects of the D1 Dopamine Receptor Agonist Dihydrexidine (DAR-0100A) on Working Memory in Schizotypal Personality Disorder. Neuropsychopharmacology 2015, 40:446-453.
111. Rossi R., Dalle-Donne I., Milzani A., Giustarini D. Oxidized forms of glutathione in peripheral blood as biomarkers of oxidative stress. Clin. Chem. 2006, 52:1406-1414.
112. Salavati B., Rajji T.K., Price R., Sun Y., Graff-Guerrero A., Daskalakis Z.J. Imaging-based neurochemistry in schizophrenia: a systematic review and implications for dysfunctional long-term potentiation. Schizophr. Bull. 2015, 41:44-56.
113. Schmitt C., Strazielle N., Ghersi-Egea J.F. Brain leukocyte infiltration initiated by peripheral inflammation or experimental autoimmune encephalomyelitis occurs through pathways connected to the CSF-filled compartments of the forebrain and midbrain. J. Neuroinflam. 2012, 9:187.
114. Schwarcz R., Bruno J.P., Muchowski P.J., Wu H.Q. Kynurenines in the mammalian brain: when physiology meets pathology. Nat. Rev. Neurosci. 2012, 13:465-477.
115. Schwarz M.J., Ackenheil M., Riedel M., Muller N. Blood-cerebrospinal fluid barrier impairment as indicator for an immune process in schizophrenia. Neurosci. Lett. 1998, 253:201-203.
116. Shamy M.C., Zai C., Basile V.S., Kennedy J.L., Muller D.J., Masellis M. Ethical and policy considerations in the application of pharmacogenomic testing for tardive dyskinesia: case study of the dopamine D3 receptor. Curr. Pharmacogenomics Person. Med. 2011, 9:94-101.
117. Siever L.J., Davis K.L. The pathophysiology of schizophrenia disorders: perspectives from the spectrum. Am. J. Psychiatry 2004, 161:398-413.
118. Silva-Adaya D., Gonsebatt M.E., Guevara J. Thioredoxin system regulation in the central nervous system: experimental models and clinical evidence. Oxid. Med. Cell Longev. 2014, 2014:590808.
119. Soderlund J., Schroder J., Nordin C., Samuelsson M., Walther-Jallow L., Karlsson H., Erhardt S., Engberg G. Activation of brain interleukin-1beta in schizophrenia. Mol. Psychiatry 2009, 14:1069-1071.
120. Song C., Li X., Kang Z., Kadotomi Y. Omega-3 fatty acid ethyl-eicosapentaenoate attenuates IL-1beta-induced changes in dopamine and metabolites in the shell of the nucleus accumbens: involved with PLA2 activity and corticosterone secretion. Neuropsychopharmacology 2007, 32:736-744.
121. Song X., Fan X., Li X., Zhang W., Gao J., Zhao J., Harrington A., Ziedonis D., Lv L. Changes in pro-inflammatory cytokines and body weight during 6-month risperidone treatment in drug naive, first-episode schizophrenia. Psychopharmacology (Berl) 2014, 231:319-325.
122. Sousa N., Almeida O.F. Disconnection and reconnection: the morphological basis of (mal)adaptation to stress. Trends Neurosci. 2012, 35:742-751.
123. Sullivan P.F., Fan C., Perou C.M. Evaluating the comparability of gene expression in blood and brain. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2006, 141B:261-268.
124. Takano A., Arakawa R., Ito H., Tateno A., Takahashi H., Matsumoto R., Okubo Y., Suhara T. Peripheral benzodiazepine receptors in patients with chronic schizophrenia: a PET study with [11C]DAA1106. Int. J. Neuropsychopharmacol. 2010, 13:943-950.
125. Umbricht D., Alberati D., Martin-Facklam M., Borroni E., Youssef E.A., Ostland M., Wallace T.L., Knoflach F., Dorflinger E., Wettstein J.G., Bausch A., Garibaldi G., Santarelli L. A randomized, double-blind, proof-of-concept study of the effect of bitopertin, a glycine reuptake 2 inhibitor, on negative symptoms of schizophrenia. JAMA Psychiatry 2014.
126. van Berckel B.N., Bossong M.G., Boellaard R., Kloet R., Schuitemaker A., Caspers E., Luurtsema G., Windhorst A.D., Cahn W., Lammertsma A.A., Kahn R.S. Microglia activation in recent-onset schizophrenia: a quantitative (R)-[11C]PK11195 positron emission tomography study. Biol. Psychiatry 2008, 64:820-822.
127. van Beveren N.J., Buitendijk G.H., Swagemakers S., Krab L.C., Roder C., de Haan L., van der Spek P., Elgersma Y. Marked reduction of AKT1 expression and deregulation of AKT1-associated pathways in peripheral blood mononuclear cells of schizophrenia patients. PloS One 2012, 7:e32618.
128. van Erp T.G., Guella I., Vawter M.P., Turner J., Brown G.G., McCarthy G., Greve D.N., Glover G.H., Calhoun V.D., Lim K.O., Bustillo J.R., Belger A., Ford J.M., Mathalon D.H., Diaz M., Preda A., Nguyen D., Macciardi F., Potkin S.G. Schizophrenia miR-137 locus risk genotype is associated with dorsolateral prefrontal cortex hyperactivation. Biol. Psychiatry 2014, 75:398-405.
129. Volpi S., Potkin S.G., Malhotra A.K., Licamele L., Lavedan C. Applicability of a genetic signature for enhanced iloperidone efficacy in the treatment of schizophrenia. J. Clin. Psychiatry 2009, 70:801-809.
130. Wake H., Moorhouse A.J., Miyamoto A., Nabekura J. Microglia: actively surveying and shaping neuronal circuit structure and function. Trends Neurosci. 2013, 36:209-217.
131. Walton E., Geisler D., Hass J., Liu J., Turner J., Yendiki A., Smolka M.N., Ho B.C., Manoach D.S., Gollub R.L., Roessner V., Calhoun V.D., Ehrlich S. The impact of genome-wide supported schizophrenia risk variants in the neurogranin gene on brain structure and function. PloS One 2013, 8:e76815.
132. Wang J.X., Rogers L.M., Gross E.Z., Ryals A.J., Dokucu M.E., Brandstatt K.L., Hermiller M.S., Voss J.L. Targeted enhancement of cortical-hippocampal brain networks and associative memory. Science (New York, N. Y.) 2014, 345:1054-1057.
133. Weiner M.W., Veitch D.P., Aisen P.S., Beckett L.A., Cairns N.J., Green R.C., Harvey D., Jack C.R., Jagust W., Liu E., Morris J.C., Petersen R.C., Saykin A.J., Schmidt M.E., Shaw L., Shen L., Siuciak J.A., Soares H., Toga A.W., Trojanowski J.Q. The Alzheimer's disease neuroimaging initiative: a review of papers published since its inception. Alzheimers Dement 2013, 9:e111-e194.
134. Xie L., Kang H., Xu Q., Chen M.J., Liao Y., Thiyagarajan M., O'Donnell J., Christensen D.J., Nicholson C., Iliff J.J., Takano T., Deane R., Nedergaard M. Sleep drives metabolite clearance from the adult brain. Science (New York, N. Y.) 2013, 342:373-377.
135. Yelmo-Cruz S., Morera-Fumero A.L., Abreu-Gonzalez P. S100B and schizophrenia. Psychiatry Clin. Neurosci. 2013, 67:67-75.
136. Yu Z., Kastenmuller G., He Y., Belcredi P., Moller G., Prehn C., Mendes J., Wahl S., Roemisch-Margl W., Ceglarek U., Polonikov A., Dahmen N., Prokisch H., Xie L., Li Y., Wichmann H.E., Peters A., Kronenberg F., Suhre K., Adamski J., Illig T., Wang-Sattler R. Differences between human plasma and serum metabolite profiles. PloS One 2011, 6:e21230.
137. Yuen E.Y., Wei J., Liu W., Zhong P., Li X., Yan Z. Repeated stress causes cognitive impairment by suppressing glutamate receptor expression and function in prefrontal cortex. Neuron 2012, 73:962-977.
138. Zhang F., Xu Y., Shugart Y.Y., Yue W., Qi G., Yuan G., Cheng Z., Yao J., Wang J., Wang G., Cao H., Guo W., Zhou Z., Wang Z., Tian L., Jin C., Yuan J., Liu C., Zhang D. Converging evidence implicates the abnormal MicroRNA system in schizophrenia. Schizophr. Bull. 2014.
139. Zhang J.P., Malhotra A.K. Pharmacogenetics and antipsychotics: therapeutic efficacy and side effects prediction. Expert Opin. Drug. Metab. Toxicol. 2011, 7:9-37.
140. Zhang X.Y., da Chen, Xiu C., Wang M.H., Qi F., Sun L.Y., Chen H.Q., He S., Wu S.C., Haile G.Y., Kosten C.N., Lu T.A., Kosten, T.R.L. The novel oxidative stress marker thioredoxin is increased in first-episode schizophrenic patients. Schizophr. Res. 2009, 113:151-157.
141. Zhu F., Zheng Y., Ding Y.Q., Liu Y., Zhang X., Wu R., Guo X., Zhao J. Minocycline and risperidone prevent microglia activation and rescue behavioral deficits induced by neonatal intrahippocampal injection of lipopolysaccharide in rats. PloS one 2014, 9:e93966.
142. Zunszain P.A., Anacker C., Cattaneo A., Choudhury S., Musaelyan K., Myint A.M., Thuret S., Price J., Pariante C.M. Interleukin-1beta: a new regulator of the kynurenine pathway affecting human hippocampal neurogenesis. Neuropsychopharmacology 2012, 37:939-949.